Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FluoroPharma has reported positive Phase I safety results for CardioPET, the company's novel cardiac imaging product.
Subscribe to our email newsletter
The trial was designed to evaluate safety, distribution and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects and patients with coronary artery disease (CAD).
According to Alan Fischman, principal investigator of the study, the CardioPET device performed well in both healthy volunteers and patients with CAD. It also achieved all safety endpoints and experienced no safety issues.
CardioPET allows assessment of acute and chronic coronary artery disease while patients are at rest. FluoroPharma anticipates that CardioPET may be an accurate alternative to standard treadmill stress-testing and for patients that are unable to exercise.